Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination

Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination

Abstract Infection is the most common cause of mortality early in life, yet the broad potential of immunization is not fully realized in this vulnerable population. Most vaccines are administered during infancy and childhood, but in some cases the full benefit of vaccination is not realized in-part....

Full description

Bibliographic Details
Main Authors: David J. Dowling, Soumik Barman, Alyson J. Smith, Francesco Borriello, Danielle Chaney, Spencer E. Brightman, Gandolina Melhem, Byron Brook, Manisha Menon, Dheeraj Soni, Simone Schüller, Karthik Siram, Etsuro Nanishi, Hélène G. Bazin, David J. Burkhart, Ofer Levy, Jay T. Evans
Format: Article
Language:English
Published: Nature Portfolio 2022-10-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-20346-w

Internet

https://doi.org/10.1038/s41598-022-20346-w

Similar Items